ACAD
36.32
+0.49
+1.37%
AEMD
0.967
-0.013
-1.2857%
APRI
1.81
-0.01
-0.55%
ARNA
27.29
-0.02
-0.07%
ATEC
4.18
+0.06
+1.46%
CNAT
5.104
+0.094
+1.8802%
CRXM
0.137
+0.034
+32.9767%
CYTX
0.485
+0.02
+4.301%
DXCM
44.9
-0.08
-0.18%
GNMK
7.86
+0.02
+0.26%
HALO
17.84
+0.07
+0.39%
ILMN
209.63
+4.45
+2.17%
INNV
0.087
0.00
0.00%
INO
6.3
+0.05
+0.80%
ISCO
1.65
+0.11
+7.14%
ISIS
57.56
0.00
0.00%
LGND
144.7
+1.35
+0.94%
LPTN
2.93
-2.93
-100.00%
MBVX
0.71
-0.03
-4.03%
MEIP
2.63
+0.01
+0.38%
MNOV
6.15
-0.04
-0.65%
MRTX
15.832
+0.282
+1.8109%
MSTX
0.13
-0.01
0.00%
NBIX
59.406
+0.446
+0.756%
NUVA
55.32
+0.75
+1.37%
ONCS
1.26
-0.03
-2.33%
ONVO
1.629
+0.229
+16.3857%
OREX
1.79
-0.03
-1.65%
OTIC
3.425
-0.05
-1.439%
QDEL
41.65
-0.3
-0.72%
RCPT
231.96
0.00
0.00%
RGLS
1.22
-0.03
-2.40%
RMD
79.29
+0.5
+0.63%
SCIE
0
0.00
0.00%
SPHS
2.321
+0.081
+3.616%
SRNE
2.73
+0.23
+9.20%
TROV
0.807
-0.002
-0.2472%
VICL
2.34
-0.04
-1.68%
VOLC
18
0.00
0.00%
ZGNX
40
+0.35
+0.88%
ACAD
36.32
+0.49
+1.37%
AEMD
0.967
-0.013
-1.2857%
APRI
1.81
-0.01
-0.55%
ARNA
27.29
-0.02
-0.07%
ATEC
4.18
+0.06
+1.46%
CNAT
5.104
+0.094
+1.8802%
CRXM
0.137
+0.034
+32.9767%
CYTX
0.485
+0.02
+4.301%
DXCM
44.9
-0.08
-0.18%
GNMK
7.86
+0.02
+0.26%
HALO
17.84
+0.07
+0.39%
ILMN
209.63
+4.45
+2.17%
INNV
0.087
0.00
0.00%
INO
6.3
+0.05
+0.80%
ISCO
1.65
+0.11
+7.14%
ISIS
57.56
0.00
0.00%
LGND
144.7
+1.35
+0.94%
LPTN
2.93
-2.93
-100.00%
MBVX
0.71
-0.03
-4.03%
MEIP
2.63
+0.01
+0.38%
MNOV
6.15
-0.04
-0.65%
MRTX
15.832
+0.282
+1.8109%
MSTX
0.13
-0.01
0.00%
NBIX
59.406
+0.446
+0.756%
NUVA
55.32
+0.75
+1.37%
ONCS
1.26
-0.03
-2.33%
ONVO
1.629
+0.229
+16.3857%
OREX
1.79
-0.03
-1.65%
OTIC
3.425
-0.05
-1.439%
QDEL
41.65
-0.3
-0.72%
RCPT
231.96
0.00
0.00%
RGLS
1.22
-0.03
-2.40%
RMD
79.29
+0.5
+0.63%
SCIE
0
0.00
0.00%
SPHS
2.321
+0.081
+3.616%
SRNE
2.73
+0.23
+9.20%
TROV
0.807
-0.002
-0.2472%
VICL
2.34
-0.04
-1.68%
VOLC
18
0.00
0.00%
ZGNX
40
+0.35
+0.88%
Home » Archive by Category

Xconomy

While You Were Sleeping: ResMed Builds an Empire in the Cloud

April 25, 2017 – 5:00 am

Over the past 28 years or so, ResMed (NYSE: RMD) has built an empire around its respiratory devices for managing sleep apnea and other forms of “sleep-disordered breathing.” In the fiscal year that…

[[Click headline to continue reading.]]

Becton Dickinson Aims Beyond Diabetes with $24B Bard Deal

April 23, 2017 – 9:27 pm

In a medical technology merger with implications for the healthcare sector in the United States and beyond, Becton Dickinson is acquiring C.R. Bard for $24 billion to tap into the growing markets for…

[[Click headline to continue reading.]]

Bio Roundup: Spinraza Woes, Science March, Baseline Launch & More

April 21, 2017 – 3:15 am

Rumblings of a new Obamacare replacement surfaced this week, while scientists and their supporters prepared for Saturday’s—a.k.a. Earth Day’s—nationwide Marches for Science….

[[Click headline to continue reading.]]

Bio Roundup: Spinraza Woes, Science March, Baseline Launch & More

April 21, 2017 – 3:15 am

Rumblings of a new Obamacare replacement surfaced this week, while scientists and their supporters prepared for Saturday’s—a.k.a. Earth Day’s—nationwide Marches for Science….

[[Click headline to continue reading.]]

Request Your Invitation to Xconomy’s Elite Napa Summit June 8-9

April 20, 2017 – 8:23 pm

  Nobel Laureate David Baltimore. Microbiome AND supercomputer pioneer Larry Smarr. Intellectual Ventures’ Nathan Myhrvold. Nicole Glaros of Techstars. These are just a few of the visionary…

[[Click headline to continue reading.]]

Phoenix Shops Its Cancer Drug as Potential Alzheimer’s Treatment

April 20, 2017 – 3:00 am

San Antonio — George Perry, a scientist at the University of Texas at San Antonio, has long proposed that drug developers and researchers need to look earlier into the roots of Alzheimer’s…

[[Click headline to continue reading.]]

“Our Son’s Fate”: Parents Fighting for Kids’ Spine Drug Eye New Data

April 20, 2017 – 2:53 am

Melissa Marotta pulled no punches to get her three-year-old son C.J., who has the genetic disease spinal muscular atrophy, access to nusinersen (Spinraza), the first approved drug for his condition….

[[Click headline to continue reading.]]

Want to Communicate Your Science? First, Step Back

April 19, 2017 – 1:55 am

Think for a moment about the words and phrases that life science researchers and executives use on a daily basis. I’m talking about the seemingly simple phrases like “investigational drug,” “novel…

[[Click headline to continue reading.]]

Bio Roundup: CRISPR Appeal, Bristol Deals, Stock Pumping & More

April 14, 2017 – 2:00 am

It may have been a short holiday week, but there was plenty of news on the CRISPR front. In the ongoing battle for rights to the landmark gene editing technology, the faction led by the University of…

[[Click headline to continue reading.]]

Tocagen IPO Raises $85M to Test Gene Therapy in Brain Cancer Trials

April 13, 2017 – 9:45 am

Tocagen raised $85 million in its stock market debut today, and underwriters saw enough demand to increase the number of shares in the initial public offering. Tocagen has been developing a gene…

[[Click headline to continue reading.]]